Jakafi and Vesicare drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Jakafi (ruxolitinib phosphate) and Vesicare (solifenacin succinate). Common drug interactions include tooth infection among females and contusion among males.

The phase IV clinical study analyzes what interactions people have when they take Jakafi and Vesicare. It is created by eHealthMe based on reports of 90 people who take the same drugs from the FDA, and is updated regularly.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.

What is Vesicare?

Vesicare has active ingredients of solifenacin succinate. It is often used in urge incontinence. eHealthMe is studying from 30,655 Vesicare users. Check the latest studies of Vesicare.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

90 people who take Jakafi and Vesicare together, and have interactions are studied.

What are the common drug interactions of Jakafi and Vesicare, by gender? *:

female:

Tooth infection
Fatigue (feeling of tiredness)
Blood glucose fluctuation
Headache (pain in head)
Nausea (feeling of having an urge to vomit)
Thrombocytosis
Cheilitis (infection of lips)
Constipation
Glossitis (infection of tongue with soreness)
Injury

male:

Contusion (a type of hematoma of tissue in which capillaries)
Haemoglobin decreased
Fatigue (feeling of tiredness)
Herpes zoster
Intestinal obstruction
Abasia (inability to walk)
Drug ineffective
Neoplasm malignant (cancer tumour)
Blood glucose increased
Blood iron decreased

What are the common drug interactions of Jakafi and Vesicare, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Constipation
Dyspnoea (difficult or laboured respiration)
Injury
Intestinal obstruction
Septic shock (shock due to blood infection)
Urinary tract infection
Neoplasm malignant (cancer tumour)
Renal disorder (kidney disease)
Alopecia (absence of hair from areas of the body)
Asthenia (weakness)

What are the existing conditions these people have? *

Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 16 people, 17.78%
Essential Thrombocythaemia (chronic blood cancer): 6 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Jakafi and Vesicare?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously